DeepBio Participates in US CancerX Summit ‍to Promote Cancer Conquest Project

DeepBio, an artificial intelligence (AI)-based digital⁣ pathology company, recently attended the ‘CancerX Member Summit’ held‌ in⁢ Washington, D.C. from the 4th to the 5th (local time).

CancerX is⁣ a public-private ​partnership ⁣established to carry out the Cancer Moonshot project promoted by the ⁤Joe Biden administration in the ‌United States. This ⁣initiative brings together experts and organizations from various fields to ​innovate cancer research, accelerate the advancement of cancer treatment,‌ improve patient treatment outcomes, and optimize the​ use of cancer-related data.

The⁤ summit was attended by approximately 150 representatives from the U.S. federal ​government agencies and private and‍ public sectors involved in CancerX.‌ Keynote speeches, interactive sessions, and workshops were held, and⁣ senior officials from‌ the Department of Health ‍and Human Services (HHS) and the Office of⁣ the‍ Assistant Secretary for Health and Human Services​ (OASH) spoke about how to align federal ⁤priorities with cutting-edge digital health solutions.

Kim ⁣Sun-woo, CEO of DeepBio, participated ​in a ​high-level conversation to develop strategic ⁣initiatives related⁤ to digital innovation and create‍ scalable solutions. “Since joining CancerAx as ⁤a ⁢member last November, we have been accelerating ‍the ‌development of our pipeline with cancer conquest as ⁤our core task,” said Kim. “We will actively express our opinions through​ sessions and⁤ workshops such as the United States Core Data for Interoperability (USCDI+) to improve ⁣the interoperability and exchange of cancer-related health information.”

DeepBio, founded in 2015, is ​a medical AI development company with expertise in deep learning and cancer pathology diagnosis.⁢ The company is developing ⁤in vitro diagnostic medical ⁢device software (IVD‍ SaMD) that ​implements useful technology to lead to better treatment decisions by greatly helping medical professionals improve the accuracy of cancer diagnosis and determine prognosis.

DeepDx Prostate, DeepBio’s‌ representative prostate cancer analysis ⁤AI ⁣solution, ‌analyzes high-resolution images (whole slide tissue images)​ obtained through tissue examination​ to ‌identify ​actual cancer lesion sites.⁢ It also provides various​ key ⁤indicators such as the ‌Gleason score, which ⁣plays an important​ role in⁣ identifying the exact‌ tumor location and in medical ⁣staff’s diagnosis, prognosis‍ prediction, and‍ treatment plan establishment.